Table 2

Clinical and laboratory parameters of the 20 patients with type 2 diabetes (10 male, 10 female), measured at baseline and 2 weeks after receiving SGLT2i therapies

Parameters (mean±SD)T2DMbaselineT2DMSGLT2iP value
Weight (kg)87.45±1687.25±16NS
Blood pressure (mm Hg)
HbA1c, % (mmol/mol)*7.45 (58)±0.876.95 (52)±0.630.006
Glucose (mg/dL)158±43138±340.01
Hematocrit (%)41.6±2.841.7±3.1NS
Erythrocyte (T/L)4.7±0.354.7±0.38NS
Thrombocyte (G/L)235±56236±53NS
Uric acid (mg/dL)5.1±1.24.6±1.00.057
Bilirubin (mg/dL)0.56±0.30.62±0.290.02
ALP (U/L)65±1862±170.04
ASAT (U/L)24±623±4NS
ALAT (U/L)27±1027±8NS
Gama GT (U/L)29±1927±15NS
Creatine kinase (U/L)115±43104±25NS
CRP (mg/dL)†0.38 (0.02–1.38)0.31 (0.02–1.15)NS
Total cholesterol (mg/dL)169±48148±340.05
LDL (mg/dL)86±3379±25NS
HDL (mg/dL)52±1450±13NS
Triglyceride (mg/dL)158±92139±43NS
  • *Compared with values 3 months after receiving SGLT2i therapies.

  • †Data not normally distributed, log10 transferred for analysis and presented as mean (range).

  • ALAT, alanine aminotransferase; ALP, leukocyte phosphatase; ASAT, aspartate aminotransferase; CRP, C-reactive protein; Gamma GT, gamma-glutamyl transferase; HbA1c, glycated hemoglobin; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; NS, not significant; SGLT2i, sodium-glucose linked transporter-2 inhibitor; T2DM, type 2 diabetes mellitus.